US Patent

US8992982 — Formulation of indomethacin

Formulation · Assigned to Iceutica Pty Ltd · Expires 2030-04-23 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods for producing indomethacin particles using dry milling processes and compositions containing these particles.

USPTO Abstract

The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.

Drugs covered by this patent

Patent Metadata

Patent number
US8992982
Jurisdiction
US
Classification
Formulation
Expires
2030-04-23
Drug substance claim
No
Drug product claim
Yes
Assignee
Iceutica Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.